Literature DB >> 11155190

Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia.

J M Walenga1, W P Jeske, H L Messmore.   

Abstract

Since the reports by Weismann and Tobin in 1958 and Roberts et al. in 1964 called attention to paradoxical thrombosis in patients treated with heparin, the thrombotic aspect of the heparin-induced thrombocytopenia syndrome (HIT) has been emphasized. Yet to this day, the mechanism of thrombosis associated with HIT (HITT) is unclear. It is important to understand the etiology of HITT because of its devastating clinical consequences. We believe one rational approach to understand the mechanism underlying HITTS is to invoke Virchow's triad: stasis, vascular injury and a hypercoagulable state. A hypercoagulable state exists in all HIT patients due to platelet activation by heparin antibody binding. Thrombin generation from platelet microparticles and exposed platelet phospholipid, coupled with stasis (elderly bedridden or otherwise sedentary ill patients who comprise the majority of the HIT population), provide two risk factors that can lead to venous thrombosis. A hypercoagulable state coupled with endothelial cell dysfunction due to injury from heparin antibody, activated platelets, leukocytes, platelet microparticles, complement, atherosclerosis or medical intervention can lead to arterial thrombosis. Of patients with HIT, HITT occurs in about 25%, suggesting that a second set of patient specific risk factors, in addition to the generation of pathological heparin antibodies, determine whether HITT will develop. Interaction between activated platelets and other platelets, and with endothelial cells, leukocytes, neutrophils, monocytes and cytokines are areas of research that may provide more specific characterization of the hypercoagulable state and vascular damage. Nuances involving genetic variation in platelets, endothelial cells and immune function are also likely to be a major component of the observed variability of this disease spectrum. Virchow's triad may explain the different manifestations of HITTS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11155190     DOI: 10.1023/a:1027372901367

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  63 in total

1.  Arterial embolism occurring during systemic heparin therapy.

Authors:  R E WEISMANN; R W TOBIN
Journal:  AMA Arch Surg       Date:  1958-02

Review 2.  Interactions of neutrophils and coagulation proteins.

Authors:  S Gillis; B C Furie; B Furie
Journal:  Semin Hematol       Date:  1997-10       Impact factor: 3.851

Review 3.  P-selectin induction of tissue factor biosynthesis and expression.

Authors:  B Furie; B C Furie
Journal:  Haemostasis       Date:  1996

4.  Laboratory tests for heparin-induced thrombocytopenia: a multicenter study.

Authors:  J M Walenga; W P Jeske; J J Wood; S Ahmad; B E Lewis; M Bakhos
Journal:  Semin Hematol       Date:  1999-01       Impact factor: 3.851

Review 5.  Heparin-induced thrombocytopenia.

Authors:  B H Chong
Journal:  Br J Haematol       Date:  1995-03       Impact factor: 6.998

6.  Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation.

Authors:  A Tomer; C Masalunga; T C Abshire
Journal:  Am J Hematol       Date:  1999-05       Impact factor: 10.047

7.  Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome.

Authors:  J M Walenga; K Michal; D Hoppensteadt; J J Wood; J A Robinson; R L Bick
Journal:  Clin Appl Thromb Hemost       Date:  1999-10       Impact factor: 2.389

8.  Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents.

Authors:  W P Jeske; A M Jay; S Haas; J M Walenga
Journal:  Clin Appl Thromb Hemost       Date:  1999-10       Impact factor: 2.389

9.  Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis.

Authors:  G Arepally; S E McKenzie; X M Jiang; M Poncz; D B Cines
Journal:  Blood       Date:  1997-01-15       Impact factor: 22.113

10.  Massive acute thrombosis of the descending thoracic aorta in heparin-associated thrombocytopenia and thrombosis.

Authors:  D H Antecol; V M Walley; K L Chan
Journal:  J Am Soc Echocardiogr       Date:  1994 Sep-Oct       Impact factor: 5.251

View more
  8 in total

1.  Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.

Authors:  Lubica Rauova; Li Zhai; M Anna Kowalska; Gowthami M Arepally; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

2.  Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee.

Authors:  E Magnus Ohman; Christopher B Granger; Lawrence Rice; Charles S Abrams; Richard C Becker; Peter B Berger; Neal S Kleiman; David Moliterno; Stephan Moll; Jo E Rodgers; Stephen S Steinhubl; Victor F Tapson; Peter Sinnaeve; Kevin J Anstrom
Journal:  J Thromb Thrombolysis       Date:  2005-02       Impact factor: 2.300

3.  Proteomics of microparticles after deep venous thrombosis.

Authors:  Eduardo Ramacciotti; Angela E Hawley; Shirley K Wrobleski; Daniel D Myers; John R Strahler; Philip C Andrews; Kenneth E Guire; Peter K Henke; Thomas W Wakefield
Journal:  Thromb Res       Date:  2010-02-13       Impact factor: 3.944

Review 4.  Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.

Authors:  Daniela R Junqueira; Liliane M Zorzela; Edson Perini
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

5.  Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion.

Authors:  Zhihua Xiao; Gian P Visentin; Kannayakanahalli M Dayananda; Sriram Neelamegham
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

6.  Effectiveness of a clinical decision support system to identify heparin induced thrombocytopenia.

Authors:  Jeffrey M Riggio; Mandelin K Cooper; Benjamin E Leiby; Jeanine M Walenga; Geno J Merli; Jonathan E Gottlieb
Journal:  J Thromb Thrombolysis       Date:  2008-10-07       Impact factor: 2.300

7.  Microparticle surface protein are associated with experimental venous thrombosis: a preliminary study.

Authors:  Newaj M Abdullah; Maureen Kachman; Angela Walker; Angela E Hawley; Shriley K Wrobleski; Daniel D Myers; John R Strahler; Philip C Andrews; Goerge C Michailidis; Eduardo Ramacciotti; Peter K Henke; Thomas W Wakefield
Journal:  Clin Appl Thromb Hemost       Date:  2009 Mar-Apr       Impact factor: 2.389

Review 8.  The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation.

Authors:  Stacy P Ardoin; David S Pisetsky
Journal:  Mod Rheumatol       Date:  2008-04-17       Impact factor: 3.023

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.